Senseonics Holdings, Inc.
HealthcareNASDAQ:SENS · NASDAQ Global Select
-$0.15 today
Vol 0.52M · Avg 0.71M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-113.2%
avg -312.7%
ROIC
-66.7%
avg -595.8%
ROA
-54.7%
avg -159.3%
Analysis
ROA is currently the strongest return metric at -54.7% versus its period average of -159.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Timothy T. Goodnow | President, Chief Executive Officer & Director | $1.30M | — | 64 | $231,874.00 | 0.56% |
Mukul Jain | Chief Operating Officer | $945,166.00 | — | 53 | $517,057.00 | 1.24% |
Kenneth L. Horton | General Counsel & Corporate Development Advisor | $750,712.00 | — | 59 | $295,057.00 | 0.71% |
Frederick T. Sullivan | Chief Financial Officer, Secretary & Treasurer | $692,599.00 | — | 44 | $231,874.00 | 0.56% |
Brian Hansen | Chief Commercial Officer & Director | — | — | 58 | $132,357.00 | 0.32% |
Francine Ratner Kaufman | Chief Medical Officer & Director | — | — | 75 | $86,935.00 | 0.21% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$510,932.11
Sells
1
$101,022.70
Net Sentiment
+$409,909.41
Net buying
Most Active
ROEDER DOUGLAS A
3 transactions
Analysis
Insiders reported 6 buys worth $510,932.11 and 1 sells worth $101,022.70 over the last 12 months. That adds up to net buying of $409,909.41. ROEDER DOUGLAS A was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +31.9% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +31.9% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
NeuroPace, Inc.
NASDAQ:NPCE
$533.23M
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$520.97M
Cerus Corporation
NASDAQ:CERS
$512.94M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Who manages SENS?
Senseonics Holdings, Inc. (SENS) lists 6 active executives. The top listed executive is Timothy T. Goodnow, President, Chief Executive Officer & Director.
Are SENS insiders buying or selling?
Recent insider activity shows net buying of $9.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.